Enterovirus A vaccine - Medigen Vaccinology/Adimmune

Drug Profile

Enterovirus A vaccine - Medigen Vaccinology/Adimmune

Alternative Names: EV71 vaccine inactivated - Medigen; Inactive whole monovalent EV71 virion vaccine

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator National Health Research Institutes
  • Developer Adimmune Corporation; Medigen Vaccinology Corp; National Health Research Institutes
  • Class Enterovirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Enterovirus A infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Enterovirus A infections(Prevention, In volunteers, In adults) in Taiwan (Parenteral)
  • 01 Sep 2014 Phase-II clinical trials in Enterovirus A infections (In volunteers, In infants, In children, Prevention) in Taiwan (Parenteral)
  • 01 Dec 2010 Phase-I clinical trials in Enterovirus A infections (in volunteers, in adults, prevention) in Taiwan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top